GANX Earnings Date: Nov 11, 2026 (Estimated) — Gain Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is GANX's next earnings date?
Gain Therapeutics, Inc. (GANX) is expected to report Q3 2026 earnings on Wednesday, November 11, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.13 on revenue of $33,333.
How did GANX do in its last earnings report?
In its most recent report on Aug 11, 2026 (Q2 2026), Gain Therapeutics, Inc. posted EPS of -$0.11 versus the -$0.14 estimate, a beat of 26.7%. Revenue was $0 against a $33,333 estimate. The stock's 1-day post-earnings move was +16.4%.
How much does GANX stock move after earnings?
GANX beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.6% (up or down) in the day after earnings.
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | Q2 2026 | -0.14 | -0.11 | +26.67% | $0 | ✅ Beat | +16.38% | +15.25% | -2.82% |
| 2026-05-11 | Q1 2026 | -0.14 | -0.13 | +7.14% | $0 | ✅ Beat | +0.00% | -3.85% | -9.34% |
| 2026-03-26 | Q4 2025 | -0.14 | -0.11 | +21.43% | $0 | ✅ Beat | -3.57% | -1.02% | +0.51% |
| 2025-11-12 | Q3 2025 | -0.15 | -0.15 | +0.00% | $0 | ➖ Inline | +10.07% | +6.34% | +53.36% |
| 2025-08-12 | Q2 2025 | -0.17 | -0.19 | -11.76% | $0 | ❌ Miss | +4.79% | +21.23% | +18.49% |
| 2025-03-27 | Q4 2024 | -0.17 | -0.11 | +35.29% | $0 | ✅ Beat | -0.96% | -9.57% | -9.33% |
| 2024-11-14 | Q3 2024 | -0.21 | -0.17 | +19.05% | $0 | ✅ Beat | +5.73% | -7.16% | -4.87% |
| 2024-05-14 | Q1 2024 | -0.29 | -0.22 | +24.14% | $0 | ✅ Beat | -3.31% | +3.72% | -12.81% |
Showing last 8 quarters.